Literature DB >> 15448007

The prognostic value of BCAR1 in patients with primary breast cancer.

Lambert C J Dorssers1, Nicolai Grebenchtchikov, Arend Brinkman, Maxime P Look, Simone P J van Broekhoven, Danielle de Jong, Harry A Peters, Henk Portengen, Marion E Meijer-van Gelder, Jan G M Klijn, Doorlene T H van Tienoven, Anneke Geurts-Moespot, Paul N Span, John A Foekens, Fred C G J Sweep.   

Abstract

PURPOSE: BCAR1, the human homologue of the rat p130Cas protein, was identified in a functional screen for human breast cancer cell proliferation resistant to antiestrogen drugs. Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens. EXPERIMENTAL
DESIGN: A specific ELISA was developed to measure BCAR1 protein levels in 2593 primary breast tumor cytosols. Tumor levels of BCAR1 were correlated with relapse-free survival (RFS) and overall survival (OS) and compared with collected data on urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1).
RESULTS: In tumor cytosols, BCAR1 protein levels varied between 0.02 and 23 ng/mg protein. BCAR1 levels exhibited a positive correlation with steroid hormone receptor levels, age and menopausal status, and uPA and PAI-1 levels. The level of BCAR1 (continuous or categorized as low, intermediate, or high) was inversely related with RFS and OS time. Multivariate analysis showed that BCAR1 levels contributed independently to a base model containing the traditional prognostic factors for both RFS and OS (both P < 0.0001). When added together with uPA and PAI-1 in the multivariate model, BCAR1 contributed independently of PAI-1 and was favored over uPA. Interaction tests allowed for additional analyses of BCAR1 protein levels in clinically relevant subgroups stratified by nodal and menopausal status.
CONCLUSIONS: The quantitative BCAR1 protein level represents a prognostic factor for RFS and OS in primary breast cancer, independent of the traditional prognostic factors and the other novel marker PAI-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448007     DOI: 10.1158/1078-0432.CCR-04-0444

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

Authors:  Yingchun Wang; Jonathan A Kelber; Hop S Tran Cao; Greg T Cantin; Rui Lin; Wei Wang; Sharmeela Kaushal; Jeanne M Bristow; Thomas S Edgington; Robert M Hoffman; Michael Bouvet; John R Yates; Richard L Klemke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.

Authors:  Alpa M Nick; Rebecca L Stone; Guillermo Armaiz-Pena; Bulent Ozpolat; Ibrahim Tekedereli; Whitney S Graybill; Charles N Landen; Gabriel Villares; Pablo Vivas-Mejia; Justin Bottsford-Miller; Hye Sun Kim; Ju-Seog Lee; Soo Mi Kim; Keith A Baggerly; Prahlad T Ram; Michael T Deavers; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Natl Cancer Inst       Date:  2011-09-28       Impact factor: 13.506

Review 3.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

4.  BCAR3/AND-34 can signal independent of complex formation with CAS family members or the presence of p130Cas.

Authors:  Pierre Vanden Borre; Richard I Near; Anthony Makkinje; Gustavo Mostoslavsky; Adam Lerner
Journal:  Cell Signal       Date:  2011-01-22       Impact factor: 4.315

5.  Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids.

Authors:  Sophya Konstantinovsky; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2012-04-04       Impact factor: 5.150

6.  Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.

Authors:  Yann Wallez; Stefan J Riedl; Elena B Pasquale
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

7.  Roles for crk in cancer metastasis and invasion.

Authors:  Masumi Tsuda; Shinya Tanaka
Journal:  Genes Cancer       Date:  2012-05

8.  NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer.

Authors:  Yann Wallez; Peter D Mace; Elena B Pasquale; Stefan J Riedl
Journal:  Genes Cancer       Date:  2012-05

9.  Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.

Authors:  Michael S Guerrero; J Thomas Parsons; Amy H Bouton
Journal:  Genes Cancer       Date:  2012-05

Review 10.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.